Accelerate Diagnostics, Inc. (AXDX)
| Market Cap | 267.51M |
| Revenue (ttm) | 11.55M |
| Net Income (ttm) | -73.81M |
| Shares Out | 69.66M |
| EPS (ttm) | -1.24 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 351,322 |
| Open | 3.74 |
| Previous Close | 3.72 |
| Day's Range | 3.55 - 3.89 |
| 52-Week Range | 3.55 - 15.60 |
| Beta | 1.80 |
| Analysts | Buy |
| Price Target | 8.33 (+116.9%) |
| Earnings Date | Feb 21, 2022 |
About AXDX
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic sus...
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for AXDX stock is "Buy." The 12-month stock price forecast is 8.33, which is an increase of 116.93% from the latest price.
News
Accelerate Diagnostics Announces Preliminary Fourth Quarter & Full-Year 2021 Financial Results
TUCSON, Ariz., Jan. 13, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced preliminary financial results for the quarter and year ending December 31, 2021.
Accelerate Diagnostics Wins Suzhou Innovation Award to Support Continued China Commercialization Efforts
TUCSON, Ariz., Jan. 12, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) announced today that it was honored as a recipient of China's Suzhou Industrial Park's (SIP) 15th Science and Tec...
Accelerate Diagnostics to Participate Virtually in 40th Annual J. P. Morgan Healthcare Conference on January 13, 2022
TUCSON, Ariz., Dec. 29, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) announced today that the company is scheduled to present at the 40th Annual J.
Penny Stocks To Buy Now According To Insiders In December 2021
Insiders are buying these penny stocks during "tax loss season" The post Penny Stocks To Buy Now According To Insiders In December 2021 appeared first on Penny Stocks to Buy, Picks, News and Information...
New Accelerate Pheno® System Multi-Center Study Published in Clinical Infectious Diseases
TUCSON, Ariz., Nov. 22, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) today announced the publication of its Improving Outcomes and Antibiotic Stewardship (IOAS) Study in the journal ...
Accelerate Diagnostics (AXDX) Reports Q3 Loss, Lags Revenue Estimates
Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 57.14% and -11.05%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Accelerate Diagnostics Reports Third Quarter 2021 Financial Results
TUCSON, Ariz., Nov. 9, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced preliminary financial results for the third quarter for the period ended September 30, 2021, which...
Earnings Preview: Accelerate Diagnostics (AXDX) Q3 Earnings Expected to Decline
Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are These 2 Companies Next for Short Squeezes?
SmileDirectClub and Accelerate Diagnostics are super cheap right now, with very high short positions. Here's why the shorts might rupture.
Accelerate Diagnostics Schedules Call to Review 3rd Quarter 2021 Results
TUCSON, Ariz., Oct. 19, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. announced today that management will host a conference call on Tuesday, November 9, 2021, at 4:30 p.m.
Accelerate Diagnostics Announces Agreements to Exchange Approximately $51 Million in Principal Amount of Its 2.50% Co...
TUCSON, Ariz., Sept. 23, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced that it has entered into separate, privately negotiated exchange agreements with certain holders...
Accelerate Diagnostics Reports Second Quarter 2021 Financial Results
TUCSON, Ariz., Aug. 5, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the second quarter for the period ended June 30, 2021.
Accelerate Diagnostics Announces CE Mark and Availability in Europe of Fast Antimicrobial Susceptibility Test for Use...
TUCSON, Ariz., Aug. 3, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today announced that the new IVD configuration of its Accelerate PhenoTest® BC kit has been CE marked and is ready ...
This In Vitro Diagnostics Company Is Poised to Capture Its Share of a Growing Market
Its new system marks a groundbreaking advance in the field of testing for bloodstream infections.
Accelerate Diagnostics (AXDX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Accelerate Diagnostics Schedules Call to Review 2nd Quarter 2021 Results
TUCSON, Ariz., July 15, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. announced today that management will host a conference call on Thursday, August 5, 2021, at 4:30 p.m.
Up 6% in June, Is Accelerate Diagnostics a Good Buy Now?
Investors were encouraged by a recent award the company received in the effort to diagnose and treat sepsis more rapidly.
Accelerate Diagnostics Launches a Fast Antimicrobial Susceptibility Test for Use with Existing ID Systems in the Unit...
TUCSON, Ariz., July 7, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) today announced the launch of a new IVD configuration of its Accelerate PhenoTest® BC kit in the United States.
New Accelerate Pheno® Landmark Study Validates Important Clinical Benefits to Be Presented at ECCMID 2021
TUCSON, Ariz., June 30, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today announced that it will have 3 data presentations from its Improving Outcomes and Antibiotic Stewardship (IOA...
New Strong Sell Stocks for June 2nd
BEP, AXDX, FURY, KBAL, and LUNA have been added to the Zacks Rank #5 (Strong Sell) List on June 2, 2021
New Strong Sell Stocks for May 20th
AXDX, CRIS, FSTR, GO, and PRLB have been added to the Zacks Rank #5 (Strong Sell) List on May 20, 2021
Accelerate Diagnostics to Participate in William Blair 41st Annual Growth Stock Conference on June 3, 2021
TUCSON, Ariz., May 19, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that Chief Executive Officer, Jack Phillips, and Chief Financial Officer, Steve Reichling, will pr...
New Strong Sell Stocks for May 14th
AXDX, CDR, FPAY, GCI, and IRTC have been added to the Zacks Rank #5 (Strong Sell) List on May 14, 2021
Accelerate Diagnostics (AXDX) Reports Q1 Loss, Misses Revenue Estimates
Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of -24.24% and -29.07%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Accelerate Diagnostics Reports First Quarter 2021 Financial Results
TUCSON, Ariz., May 6, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the first quarter for the period ended March 31, 2021.